|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of psoriasis patients with hepatitis B or hepatitis C virus infection显示文摘The systemic therapies available for the management of Psoriasis(PsO) patients who cannot be treated with more conservative options, such as topical agents and/or phototherapy, with the exception of acitretin, can worsen or reactivate a chronic infection. Therefore, before administering immunosuppressive therapies with either conventional disease-modifying drugs(c DMARDs) or biological ones(b DMARDs) it is mandatory to screen patients for some infections, including hepatitis B virus(HBV) and hepatitis C virus(HCV). In particular, the patients eligible to receive an immunosuppressive drug must be screened for the following markers: antibody to hepatitis B core, antibody to hepatitis B surface antigen(anti-HBs Ag), HBs Ag, and antibody to HCV(anti-HCV). In case HBV or HCV infection is diagnosed, a close collaboration with a consultant hepatologist is needed before and during an immunosuppressive therapy. Concerning therapy with immunosuppressive drugs in PsO patients with HBV or HCV infection, data exist mainly for cyclosporine a(Cy A) or b DMARDs(etanercept, adalimumab, infliximab, ustekinumab). The natural history of HBV and HCV infection differs significantly as well as the effect of immunosuppression on the aforementioned infectious diseases. As a rule, in the case of active HBV infection, systemic immunosuppressive antipsoriatic therapies must be deferred until the infection is controlled with an adequate antiviral treatment. Inactive carriers need to receive antiviral prophylaxis 2-4 wk before starting immunosuppressive therapy, to be continued after 6-12 mo from its suspension. Due to the risk of HBV reactivation, these patients should be monitored monthly for the first 3 mo and then every 3 mo for HBV DNA load together with transaminases levels. Concerning the patients who are occult HBV carriers, the risk of HBV reactivation is very low. Therefore, these patients generally do not need antiviral prophylaxis and the sera HBs Ag and transaminases dosing can be monitored every 3 mo. Concerning PsO patients with chronic HCV infection their management with immunosuppressive drugs is less problematic as compared to those infected by HBV.In fact, HCV reactivation is an extremely rare event after administration of drugs such as CyA or tumor necrosis factor-α inhibitors. As a rule, these patients can be monitored measuring HCV RNA load, and ALT, aspartate transaminase, gamma-glutamyl-transferase, bilirubin, alkaline phosphatase, albumin and platelet every 3-6 mo. The present article provides an updated overview based on more recently reported data on monitoring and managing PsO patients who need systemic antipsoriatic treatment and have HBV or HCV infection as comorbidity. | Claudio Bonifati Viviana Lora Dario Graceffa Lorenzo Nosotti | 2016 | World Journal of Gastroenterology2016，22，28： | 6 |
| 2 | Gastrointestinal stromal tumour of the rectum: Report of a case and review of literature显示文摘Gastrointestinal stromal tumour (GIST) is a rare tumour of the gastrointestinal tract which does not generally originate in the rectum. The authors describe a case of a 70-year-old man who underwent an anterior resection of the rectum for a low-risk GIST. The patient was not given adjuvant chemotherapy with imatinib and is still disease-free 30 mo after surgery. The authors conclude that although rectal GIST is extremely uncommon, it should be included in differential diagnosis when a tumour in the rectum is detected. Biopsy of the tumour is essential, since this makes it possible to reach a sure preoperative diagnosis based on the immunohistological features of the CD117 and CD34. Although complete surgical resection with negative tumour margins is the principal curative procedure for primary and non-metastatic tumours, further studies are still needed for the determination of the most effective treatment strategy for patients with rectal GIST. | Nello Grassi Calogero Cipolla Adriana Torcivia Stefano Mandalà Giuseppa Graceffa Alessandro Bottino Federica Latteri | 2008 | World Journal of Gastroenterology2008，14，8： | 6 |
| 3 | Capillaroscopy in psoriatic and rheumatoid arthritis: a useful tool for differential diagnosis 显示文摘 | Graceffa D Amorosi B Maiani E Bonifati C Cbi menti MS Perrieone R Di Carlo A | 2013 | Arthritis2013，，95： | 1 |
| 4 | Hashimololhyroiditis co-existent with papillary thyroid carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | Am Surg2005，71，10： | 1 |
| 5 | Hashimoto thyroiditis coexistent with papillary carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | Am Surg2005，71，3： | 1 |
| 6 | Hashimoto thyroiditis coexistent with pap-iUary thyroid carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | AM Surg2005，71，10： | 1 |
| 7 | Primary schwannoma of the thyroid gland involving the isthmus:report of a case显示文摘 | Graceffa G Cipolla C Florena AM | 2013 | Surg Today2013，43，1： | 1 |
| 8 | Hashimoto thyroiditis co- existent with papillary thy- roid carcinoma 显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | AM Surg2005，71，： | 1 |
| 9 | Hashimoto thyroiditis coexistent with papillary thyroid carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | The American surgeon2005，71，10： | 1 |
| 10 | Complement system in psoriatic arthritis:a useful marker in response prediction and monitoring of anti-TNF treatment显示文摘 | Chimenti MS Perricone C Graceffa D | | 0，，01： | 1 |
| 11 | Hashimoto thyroiditis coexistent with papillary thyroid carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | Am Surg2005，71，10： | 1 |
| 12 | The role of free radicals in asbestos-induced diseases显示文摘 | Kamp DW Graceffa P Pryor WA | 1992 | Free Radical Biol Med1992，12，： | 1 |
| 13 | LigaSure in total thy- roidectomy显示文摘 | Cipolla C Graceffa G Sandonato L | 2008 | Surg Today2008，38，6： | 1 |
| 14 | Hashimoto thyroiditis coexistent with papillary carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | | 0，，： | 1 |
| 15 | Evidence for interaction between smooth muscle tropomyosin and caldesmon 显示文摘 | Graceffa P | 1987 | FEBS Lett1987，218，： | 1 |
| 16 | the role of free radical in asbestos-induced Diseases显示文摘 | Kamp DW graceffa P pryorWA weitzman | 1992 | Free Radical Biology& Medicine1992，12，： | 1 |
| 17 | Hashimoto thyroiditis coexistent with papillary thyroid carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | 2005 | Am Surg2005，71，10： | 1 |
| 18 | Hashimoto thyroiditis coexistent with papillary thyroid carcinoma显示文摘 | Cipolla C Sandonato L Graceffa G | | 0，，： | 1 |
| 19 | Primary schwannoma of the thyroid gland involving the isthmus:report of a case 显示文摘 | Graceffa G Cipolla C Florena AM | 2013 | Surg Today2013，43，1： | 1 |
| 20 | Crystal structures of the vitamin D-binding protein and its complex with actin:structural basis of the actin-scavenger system显示文摘 | Otterbein R Cosio C Graceffa P | 2002 | Proc Natl Acad Sci USA2002，99，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员